Of the seven signal transducers and activators of transcription that have been identified, STATs 1, 3, and 5a/5b can be activated not only by a multitude of cytokines but also by some growth factors. The data presented here demonstrate that, in contrast to activation by the cytokine, growth hormone (GH), the activation of STAT5b by the growth factor, epidermal growth factor (EGF), requires overexpression of the EGF receptor (EGFR). We have shown that EGF activates STAT5b not only in a HEK293 cell model in which the EGFR is stably overexpressed but also in the MDA-MB468 breast cancer cell line. Furthermore, EGF (but not GH) is able to activate tyrosine phosphorylation of a Tyr-699 mutant of STAT5b. Using metabolic labeling studies as well as site-directed mutagenesis, we have identified three novel EGF-induced tyrosine phosphorylation sites, Tyr-725, Tyr-740, and Tyr-743. Luciferase assays using a STAT5-specific DNA sequence demonstrate that, although Tyr-699 is absolutely required for transcriptional activation, tyrosines 725, 740, and 743 may be involved in a negative regulation of transcription. Because overexpression of the EGFR is common in many cancers, including advanced breast cancer, characterization of EGF-induced STAT5b may have direct implications in therapeutic applications.
No takes yet. Share an insight, caveat, or question.
Kloth et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: